Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Chiesi
Thumbnail
October 12, 2021

Idorsia’s Fabry flop puts focus on gene therapies

But questions about gene therapy safety could benefit the enzyme-replacement therapy incumbents.

Thumbnail
June 02, 2021

US FDA approval tracker: May 2021

Article image
Vantage logo
February 24, 2021

Hints of a quickening emerge in accelerated approval conversions

Article image
Vantage logo
December 16, 2019

The other shoe drops for Gossamer’s GB001

Novartis’s similarly acting fevipiprant had failed in asthma in October, and today it fails in the more important severe setting.

Vantage logo
February 15, 2018

Santhera becomes third group to buy into novel respiratory mechanism

Vantage logo
January 26, 2018

Snippet roundup: High times for cannabis companies and Indivior

Article image
Vantage logo
September 19, 2017

One chance for Glaxo’s triple

The UK company's triple combo just got US approval, and now the group must meet rising analyst expectations.

Vantage logo
September 08, 2017

Upcoming events – GSK’s triple COPD play and data for Xtandi in earlier stage prostate cancer

Vantage logo
December 15, 2016

Eucrisa thumbs up validates Pfizer’s takeover strategy – partly

Vantage logo
November 21, 2016

Can Glaxo’s COPD triple play a solo act?

Vantage logo
June 17, 2016

New data Spark haemophilia B gene therapy battle

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

August 12, 2022

Q2 Roundup Infographic

August 10, 2022

Q2 Roundup eBook

View more...

Editor's Picks

Vantage logo
July 27, 2022

Aids 2022 preview – Gilead shoots for an HIV cure

Vantage logo
July 21, 2022

Private equity gets serious about drug development

Vantage logo
July 18, 2022

Unpacking Royalty Pharma

Vantage logo
July 19, 2022

No plain sailing for Novartis’s PD-1 plan

Vantage logo
July 26, 2022

Move over Aduhelm, it’s tofersen’s turn

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.